Mesoblast (NASDAQ:MESO) Shares Gap Down – Time to Sell?

Mesoblast Limited (NASDAQ:MESO)’s share price gapped down prior to trading on Friday . The stock had previously closed at $16.76, but opened at $14.96. Mesoblast shares last traded at $14.69, with a volume of 112,482 shares traded.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday, September 24th. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Finally, Piper Sandler boosted their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Mesoblast Stock Down 12.8 %

The business has a 50-day moving average of $10.39 and a 200-day moving average of $8.23. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Hedge Funds Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in Mesoblast in the second quarter worth approximately $562,000. XY Capital Ltd bought a new stake in shares of Mesoblast during the 3rd quarter worth about $244,000. Jane Street Group LLC increased its holdings in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after acquiring an additional 26,959 shares during the last quarter. Creative Planning bought a new position in shares of Mesoblast in the 3rd quarter valued at approximately $147,000. Finally, XTX Topco Ltd bought a new position in shares of Mesoblast in the 2nd quarter valued at approximately $103,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.